The niacinamide-containing tirzepatide formulations discussed earlier are partly motivated by this logic, since niacinamide is a NAD+ precursor
Its main role is to turn fat into energy by assisting in the transport of fatty acids into the mitochondria, the energy powerhouses of our cells
These medications work by activating GLP-1 receptors, helping people feel fuller longer, eat less, and lose weight
Currently, the SURPASS-CVOT trial is evaluating the impact of dulaglutide and tirzepatide on cardiovascular events in patients with T2D (NCT04255433)
Most patients report noticeable reductions in hunger and food cravings within 3-7 days of starting injections, even before any weight appears on the scale
SREBP-1c, sterol regulatory element-binding protein 1c